OpenAI to expand drug-discovery AI “Rosalind” into R&D program management with Orchestra Bio acquisition
On Oct. 20, U.S. time, OpenAI acquired Orchestra Bio, which develops an operations management platform for biopharmaceutical companies. The company will integrate it into its life sciences product suite, “Rosalind,” broadening AI’s role from research support to development program management.
